Actively Recruiting
Understanding Inflammation, InFection and Interventions in Severe Exacerbations of Cystic Fibrosis
Led by Alexander Horsley · Updated on 2026-03-24
200
Participants Needed
6
Research Sites
220 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The UNIFIED-CF study is an observational study designed to investigate the impacts of treatment given for severe pulmonary exacerbations in people living with cystic fibrosis (pwCF). Exacerbations are episodes when pwCF become more unwell, typically characterised by increased cough, sputum, and breathlessness and treated with a combination of oral and/or intravenous antibiotics. Severe exacerbations require treatment with intravenous antibiotics and impart considerable morbidity on pwCF. In this study, the investigators will recruit people at risk of severe CF exacerbations when they are well and if/when they are subsequently admitted for treatment of an exacerbation, the investigators will track symptoms and lung function during recovery, and collect blood, sputum and stool samples to allow us to explore the biological mechanisms of exacerbations and how they relate to different treatment responses. The study is event driven and will complete recruitment once 125 participants have completed treatment and follow-up for a severe exacerbation event. This study is funded by the Cystic Fibrosis Trust. This study is part of a wider programme of research, led by the PULSE-CF Innovation Hub (and hosted by the University of Manchester). The aim of the Hub is that the data from the UNIFIED-CF study will ultimately support the design of a platform clinical trial to test exacerbation-prevention interventions in CF.
CONDITIONS
Official Title
Understanding Inflammation, InFection and Interventions in Severe Exacerbations of Cystic Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
Confirmed diagnosis of cystic fibrosis (CF), defined as presence of two pathogenic CF-causing CFTR mutations AND clinical features consistent with a diagnosis of CF, OR presence of at least one pathogenic CF-causing CFTR mutation AND sweat chloride (before use of CFTR modulators) >60mmol/L AND clinical features consistent with a diagnosis of CF.
-
Receiving care from a UK Adult Cystic Fibrosis Centre taking part in the study.
-
EITHER:
• Have had at least 1 previous exacerbation of CF lung disease, treated with intravenous antibiotics, in the previous 12 months.
OR
• Enrolled in the CF-Tracker study (IRAS ID 338539) within the last 24 months (dated from date of completion of baseline Tracker visit)
-
In case of treatment for an exacerbation, likely to be treated with a ß-lactam or an anti-pseudomonal penicillin, combined with tobramycin or colistin, per CF Trust and NICE guidelines for 1st-line CF therapies.
-
Able to produce sputum (spontaneous or induced) at baseline visit.
-
Able to understand the patient information sheet, willing to consent to study protocol.
You will not qualify if you...
- When attending for the baseline visit participants should be clinically stable at the time of the visit. This is defined as no acute change in their baseline symptoms or presence of new viral symptoms. They should not be on additional antibiotics or anti-viral therapies for any reason (above their usual medications), and should have completed any such additional therapies at least 4 weeks prior.
- Extensive antibiotic allergies or intolerances that mean they could not be treated with standard CF antibiotic regimens, as outlined in section 5.6.
- Subjects with infection with Mycobacteria tuberculosis
- Subjects with active ABPA, defined as receiving treatment for ABPA currently or within the last 4 months, or those considered at risk of requiring treatment for ABPA in the next 12 months.
- Subjects receiving long term oral steroids at an equivalent dose of 10mg or more per day of prednisolone.
- Subjects receiving any other form of long term immune-suppressant therapy.
- Subjects with non-tuberculous mycobacteria (NTM) infection who are undergoing active eradication therapy. Subjects with chronic NTM infection who are not on eradication therapy, and not expecting to start this within the next 12 months, are not excluded.
- Any other condition, co-morbidity or other feature that, in the opinion of the investigator would render the subject unable to complete the protocol or unsuitable for inclusion.
- Planning on participating in a clinical trial of a novel experimental investigational medical product in the next 12 months.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Cardiff and Vale University Health Board
Cardiff, United Kingdom, CF14 4XW
Not Yet Recruiting
2
Royal Devon and Exeter Hospital (Wonford)
Exeter, United Kingdom, EX2 5DW
Not Yet Recruiting
3
Leeds Adult CF Centre
Leeds, United Kingdom, LS9 7TF
Not Yet Recruiting
4
Liverpool Heart & Chest Hospital
Liverpool, United Kingdom, L14 3PE
Not Yet Recruiting
5
Manchester Adult Cystic Fibrosis Centre
Manchester, United Kingdom, M23 9LT
Actively Recruiting
6
Newcastle Adult CF Centre
Newcastle upon Tyne, United Kingdom, NE1 4LP
Not Yet Recruiting
Research Team
A
Alexander Horsley, MA MBChB MRCP PhD FERS
CONTACT
C
Cheuk Ning Sharon Chau
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here